• Orphan Drug Designation granted for the treatment of primary immune thrombocytopenia 
• Underscores the potential of sovleplenib to address significant unmet medical needs in patients with this rare and serious autoimmune condition 
• Eligible for development incentives including 7 years of US market exclusivity upon regulatory approval 

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.